Vernagen aims for the discovery and development of mRNA-based vaccines and therapeutic biologics. Vernagen utilizes extensive basic science knowledge and chemical innovations to design mRNA platforms that will optimally produce target proteins in cells. mRNA biologics targeting immunological and genetic disorders and mRNA vaccines against infectious diseases are our current pipeline concepts. Therapeutic platforms developed by Vernagen will be validated in pre-clinical/animal models for their efficacy and safety, ultimately in human trials.